Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series

Current Medical Research and Opinion

Volumn 18, Issue 5, 2002, Pages 258-264

  Bullock, R ^a   Cameron, A ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Case series; Cognition; Dementia; Hallucinations; Parkinson's disease; Psychosis; Rivastigmine

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; APOMORPHINE; ATENOLOL; BENDROFLUMETHIAZIDE; BENSERAZIDE PLUS LEVODOPA; CABERGOLINE; CANDESARTAN; CARBIDOPA PLUS LEVODOPA; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; FERROUS SULFATE; FLUVOXAMINE; FUROSEMIDE; GLIBENCLAMIDE; ISOSORBIDE MONONITRATE; LOFEPRAMINE; LOPERAMIDE; NEUROLEPTIC AGENT; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TEMAZEPAM; TRIHEXYPHENIDYL; WARFARIN; ZOLPIDEM;

ABDOMINAL PAIN; AGED; APATHY; ARTICLE; BEHAVIOR DISORDER; BRAIN REGION; CLINICAL ARTICLE; COGNITIVE DEFECT; DEMENTIA; DRUG CHOICE; DRUG EFFICACY; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MUSCLE CRAMP; NAUSEA; PARKINSON DISEASE; PERSONALITY DISORDER; SPEECH DISORDER; URINE RETENTION; VERTIGO; VISUAL HALLUCINATION; VOMITING;

AGED; CARBAMATES; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; HALLUCINATIONS; HUMANS; MALE; PARKINSON DISEASE; PHENYLCARBAMATES; TREATMENT OUTCOME;

EID: 0036040074     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000813     Document Type: Article

References (35)

1. Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: A summary of the literature of the early 1990s
2. Temporal ordering and short-term memory deficits in Parkinson's disease
3. Abnormal gaze strategies during problem solving in Parkinson's disease
4. Parkinson's disease and dementia
5. Cerebral glucose metabolism in Parkinson's disease with and without dementia
6. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review
7. Neuroleptic sensitivity in patients with senile dementia Lewy Body type
8. Cholinesterase inhibition in Parkinson's disease
9. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double blind, placebo-controlled international study
10. Selectivity of cholinesterase inhibition
11. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition
12. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase
13. Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1 year: Differential effects across time
14. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease
15. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: Correlation with cognitive benefit
16. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial
17. Rivastigmine in the treatment of parkinsonian hallucinosis
18. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the cognitive drug research computerised assessment system
19. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: A rapid and systematic review
20. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances
21. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia
22. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
23. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
24. An efficacy and safety analysis of Exelon in Alzheimer's disease with concurrent vascular risk factors
25. Treatment of symptoms specific to patients with subcortical vascular dementia: An open label pilot study comparing rivastigmine and cardioaspirin
26. Donepezil use in Alzheimer disease
27. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
28. Donepezil in dementia with Lewy bodies: Treatment and withdrawal
29. Possible association between donepezil and worsening Parkinson's disease
30. A 24-week, double-blind, placebo controlled trial of donepezil in patients with Alzheimer's disease
31. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
32. Adverse effects associated with the use of donepezil in general practice in England
33. The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: A 12-week, multinational, comparative study
34. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia
35. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man